Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company's potential treatment for a rare disease. The FDA's Decision on BHVN's Drug Candidate The FDA agreed to review BHVN's ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults ...

The last time I wrote about Biohaven (NYSE:BHVN) it was with respect to a Seeking Alpha article entitled "Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst." ...

Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia, or SCA ...

In trading on Tuesday, shares of Biohaven Ltd (Symbol: BHVN) crossed above their 200 day moving average of $40.76, changing hands as high as $42.68 per share. Biohaven Ltd shares are currently ...